Jim Cramer on Chemours: “I Think it’s Chronically Undervalued”

The Chemours Company (NYSE:CC) is one of the stocks Jim Cramer shared his opinions on. A caller asked for guidance on the stock, and Cramer replied:

“You know, I think it’s chronically undervalued, but I have to tell you, because people continue to think that it’s got problems with forever chemicals, I don’t think it does. I think they put them behind it, but I’m not going to touch it because the plaintiffs’… that powerful.”

10 stocks receiving a massive vote of approval from Wall Street analysts

The Chemours Company (NYSE:CC) delivers specialty chemicals across industries. The company’s portfolio includes refrigerants, pigments, resins, coatings, and advanced materials used in coatings, electronics, packaging, energy, transportation, and medical applications. On September 23, Mizuho analyst John Roberts increased Chemours’ price target to $19 from $16 while maintaining an Outperform rating. The analyst noted that per- and polyfluoroalkyl substance settlement progress is favorable and that stronger market valuations support the higher target.

While we acknowledge the risk and potential of CC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CC and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.